ClinicalTrials.gg
Not yet recruitingNCT07291557Updated Nov 4, 2026

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

A Phase 2 interventional study of Prostate Only Radiation Therapy (PORT) and Prostate + Whole Pelvis Radiation Therapy (P-WPRT) in Prostate Cancer, sponsored by AHS Cancer Control Alberta. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AHS Cancer Control Alberta · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · AHS Cancer Control Alberta.

Planned enrollment
Largest of 14
250 · median 40
Started
2026
with 1 other
Phase 2
5 of 22
2 open now
Registered
21st of 22
by date

Among the 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 21st registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta, or all of them as a file.
02

Study summary

In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starting the trial.

Read the detailed description

The current treatment of high risk and very high risk localized prostate cancer is by radiation therapy (RT) and hormone therapy (ADT). RT uses radiation to kill the cancer cells while hormone therapy lowers the levels of male hormones like testosterone, which the cancer needs to grow. Radiation is targeted to the prostate and nearby tissues, which may or may not include whole pelvis radiation therapy (WPRT). The benefit of whole pelvis radiation therapy is not well understood. Therefore, clinical research is needed to assess the benefits/risks of whole pelvis radiation therapy in prostate cancer treatment. In addition to traditional cancer imaging methods like CT, MRI, and bone scan, new techniques like PSMA imaging are now available to examine prostate cancer. The PSMA scan involves a small amount of radioactive tracer (18F-PSMA-1007) being injected into the vein, which marks the prostate cancer cells for better visualization of the cancer location and spread. Because of its higher accuracy, results of PSMA scans can change how doctors plan cancer treatment, like where they aim radiation and how much they use.

In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starting the trial.

There will be two treatment groups (1) Prostate Only Radiation Therapy (PORT), and Prostate + Whole Pelvis Radiation Therapy (P-WPRT), and all participants will receive hormone therapy as part of standard of care. In addition to comparing the biochemical failure free survival (BFFS) between the two treatment groups, the study will also compare distant metastases free survival (DMFS), toxicity, patient reported outcomes and overall survival (OS).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Radiotherapy
  • PSMA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PSMA-N0M0 patients who have a documented history of High Risk localized adenocarcinoma of the prostate are eligible to participate if they meet the following eligibility criteria:

  1. Participants capable of giving written .
  2. Male.
  3. Age ≥18 years.
  4. ≤2.
  5. Patient has proven adenocarcinoma of prostate gland with an assigned Gleason score and Gleason Grade Group.
  6. ≥NCCN High-Risk localized disease as per standard imaging investigations including pelvic imaging (CT, MRI) and 99Tc bone scan. High Risk prostate cancer defined as any of the following: cT3-T4 disease OR PSA ≥20 ng/ml OR Gleason grade group 4 or 5.
  7. No documentation of regional nodal (N1) or (M1) prostate cancer on standard imaging (CT, MRI, or 99Tc bone scan).
  8. In the opinion of the treating oncologist, patient is fit to undergo radical external beam radiotherapy to the prostate.
  9. Patient commits to androgen suppression treatment as per standard of care. 10. Patient is willing to complete symptom and patient reported outcome questionnaires.

11. Patients of childbearing / should use highly effective methods, as defined by the investigator, during the study treatment period and for a period of 6 months after the last dose of radiation therapy. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.

Male patients should agree to not donate sperm during the study and for 6 months after completion of radiation therapy.

Exclusion criteria

Exclusion Criteria:

  1. Inability to complete the imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.).
  2. Any additional medical condition, serious inter-current illness or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study performance, interpretation, or compliance with radiation
  3. Patients who have initiated therapy (ADT, systemic therapy, or radiation) for their prostate cancer prior to PSMA-PET imaging.
  4. History of inflammatory bowel disease, anal stenosis, colorectal surgery, or repeated endoscopic examinations/interventions related to anorectal diseases.
  5. History of prostatectomy or previous pelvic radiotherapy.
  6. Previous within the last five years, except BCC or SCC skin or a malignancy treated curatively with no evidence of disease for ≥5 years.
  7. Bilateral hip prostheses will be ineligible for study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Prostate Only Radiation Therapy (PORT)

    Radiation therapy: prostate and surrounding tissues

    Radiation: Prostate Only Radiation Therapy (PORT)

  • Experimental
    Prostate + Whole Pelvis Radiation Therapy (P-WPRT)

    Radiation therapy: prostate and surrounding tissues + whole pelvis radiation therapy

    Radiation: Prostate + Whole Pelvis Radiation Therapy (P-WPRT)

Interventions

  • RadiationProstate Only Radiation Therapy (PORT)

    6800cGy in 25 daily fractions to the prostate and surrounding tissues

  • RadiationProstate + Whole Pelvis Radiation Therapy (P-WPRT)

    6800cGy to the prostate and surrounding tissues + 5000cGy to the whole pelvis in 25 daily fractions.

06

What researchers measure

Primary outcomes

  1. 5-year Biochemical Failure Free Survival (BFFS)

    As measured from the date of randomization to the first recorded date of biochemical failure as defined by serum PSA exceeding nadir PSA +2 ng/mL.

    Time frame: Number of events as measured from the date of randomization to 5-years.

Secondary outcomes

  1. Distant metastases-free survival (DMFS)

    Calculated from the time of randomization until the development of first distant metastasis outside the pelvic nodal regions. Patients will be censored at either the date of last follow-up or date of death.

    Time frame: As measured from the date of randomization until the development of first distant metastasis outside the pelvic nodal regions or date of death from any cause, whichever came first; assessed up to 10 years (end of extended follow-up)

  2. Acute and late toxicity as per CTCAE 5.0

    Patient toxicity will be documented as per the domains of the CTCAE v5.0.

    Time frame: Acute toxicity will be measured up to the 90 days post-radiation, and late toxicity will be monitored over the course of the study follow-up, up to 5 years post-radiation.

  3. Overall survival

    As measured form the time of randomization to the time of death from any cause.

    Time frame: As measured form the time of randomization to date of death from any cause, assessed up to 10 years (end of extended follow-up)

  4. Patient reported outcomes: IPSS

    International Prostate Symptom Score (IPSS) is a standardized questionnaire used worldwide to assess the severity of urinary symptoms. It consists of 7 questions, each scored from 0 (no symptoms) to 5 (most severe symptoms). The total score is the sum of all responses, giving a range from 0 to 35

    Time frame: Outcomes will be measured from the completion of radiation up to 90 days post-radiation, and over the course of the study follow-up, up to 5 years post-radiation.

  5. Patient reported outcomes: EQ-5D

    The 5-item EQ-5D index score will be transformed into a utility score between 0, "Worst health state," and 1, "Best health state." The index score or the cost-utility equation can be used in the quality adjusted survival analysis. For this study, the plan is to report the multidimensional utilities for comparative purposes.

    Time frame: Outcomes will be measured from the completion of radiation up to 90 days post-radiation, and over the course of the study follow-up, up to 5 years post-radiation.

  6. Patient reported outcomes: EPIC-26

    Expanded Prostate Cancer Index Composite - Short Form (EPIC-26) uses a 0-100 scale per domain, where 0 means worst function and 100 means best function. EPIC-26 overall score will be reported, as well as intra-individual change from baseline. Score changes will also be stratified by clinically minimally important differences of 5 for bowel and hormonal, 7 for urinary, and 10 for sexual domain

    Time frame: Outcomes will be measured from the completion of radiation up to 90 days post-radiation, and over the course of the study follow-up, up to 5 years post-radiation.

Other outcomes

  1. 10-year Biochemical Failure Free Survival (BFFS)

    Patient charts will be reviewed retrospectively after patients have completed clinical trial follow-up for clinical history up to 10 years postradiation. BFFS will be calculated from the time of randomization to the date to PSA relapse

    Time frame: Retrospective chart reviews will occur during long term follow-up (years 5 to 10, inclusive).

  2. 10-year Disease Free Survival (DFS)

    Patient charts will be reviewed retrospectively after patients have completed clinical trial follow-up for clinical history up to 10 years postradiation. DFS is calculated from the time of randomization to the first biochemical or clinicoradiological recurrence of disease at any site, or death due to any cause, whichever occurs earlier

    Time frame: Retrospective chart reviews will occur during long term follow-up (years 5 to 10, inclusive).

  3. 10-year Distant Metastases-Free Survival (DMFS)

    Patient charts will be reviewed retrospectively after patients have completed clinical trial follow-up for clinical history up to 10 years postradiation. DMFS will be calculated from the time of randomization until the development of first distant metastasis outside the pelvic nodal regions.

    Time frame: Retrospective chart reviews will occur during long term follow-up (years 5 to 10, inclusive).

  4. Assessment of fatigue over the course of therapy

    Patient level of fatigue will be assessed as a patient reported outcome using the validated Brief Fatigue Inventory (BFI) which will be completed at each of the AE and quality of life assessments. BFI uses a 0-10 scale per item, with 0 meaning no fatigue and 10 meaning the worst fatigue. Longitudinal scores for each patient will be correlated with therapy received and radiation dosimetry.

    Time frame: Outcomes will be measured from the completion of radiation up to 90 days post-radiation, and over the course of the study follow-up, up to 5 years post-radiation.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2031, 53 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 53 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Dec 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 18, 2025
StartEst.
Dec 2026was May 2026
Primary completionEst.
May 2031
CompletionEst.
May 2036
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 2026→Dec 2026
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date May 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07291557
Collaborators
Cross Cancer Institute
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Dec 2026 (estimated)
Primary completion
May 2031 (estimated)
Completion
May 2036 (estimated)
Last update
Nov 4, 2026

Study contacts

Lindsay Rowe, MD
Contact
Lindsay.rowe@ahs.ca
780-432-8966

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion